N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry
نویسندگان
چکیده
منابع مشابه
UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker.
Mucin O-glycosylation is characterized in cancer by aberrant expression of immature carbohydrate structures (Tn, T, and sialyl-Tn antigens). The UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferases (ppGalNAc-T) family enzymes regulate the initial steps of mucin O-glycosylation and could be responsible for the altered glycosylation observed in cancer. Considering that we ...
متن کاملHuman kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Human kallikrein gene 14 (KLK14) is a recently discovered member of the tissue kallikrein family of secreted serine proteases, which includes hK3/prostate-specific antigen, the best cancer biomarker to date. Given that KLK14 is hormonally regulated, differentially expressed in endocrine-related cancers, and a prognostic marker for breast and ovarian cancer at the mRNA level, we hypothesize that...
متن کاملCan Prostate Specific Antigen Be Used as New Biomarker for Early Diagnosis of Breast Cancer?
Introduction: As a glycoprotein, Plasma Prostate-Specific Antigen (PSA) is mainly produced by prostate epithelial cells and is used as a major diagnostic tool for prostate cancer. A group of researchers relate the elevated number of estrogen receptors in breast cancer samples to the over-production of PSA in this type of cancer. Therefore, the present study aimed to determine the participants' ...
متن کاملCell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
As conventional biomarkers for defining breast cancer (BC) subtypes are not always capable of predicting prognosis, search for new biomarkers which can be easily detected by liquid biopsy is ongoing. It has long been known that cell-free DNA (CF-DNA) could be a promising diagnostic and prognostic marker in different tumor types, although its prognostic value in BC is yet to be confirmed. This r...
متن کاملHGF-MET as a breast cancer biomarker
in preclinical studies, few clinical trials of MET inhibitors have demonstrated the expected therapeutic benefits. This inconsistency raises the possibilities that there are different subsets of MET/HGF-aberrant breast cancer with different responses to MET/HGF-targeted therapies and that MET inhibitors benefit only a particular subgroup of patients. To fully realize the benefits of MET inhibit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMC Cancer
سال: 2010
ISSN: 1471-2407
DOI: 10.1186/1471-2407-10-123